Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Par Petroleum Corporation’s $107 million acquisition of Koko’oha Investments, Inc.’s wholly-owned subsidiary Mid Pac Petroleum, LLC would likely be anticompetitive. Under the order, first announced in March 2015, Par was required to terminate its storage and throughput rights […]
Tag Archives: Bureau of Competition Competition
FTC Approves Final Order Preserving Competition in Generic Drug Market for Treating Dry Mouth and Biliary Cirrhosis
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Impax Laboratories Inc.’s acquisition of CorePharma, LLC would likely be anticompetitive. Under the order, first announced in March 2015, the pharmaceutical companies have agreed to divest CorePharma’s rights and assets to generic pilocarpine tablets, which are used to […]
FTC Staff Expresses Concern that New York’s Certificate of Public Advantage Regulations Can Harm Competition
In a letter to the New York State Department of Health, Federal Trade Commission staff expressed concern that the New York State’s Certificate of Public Advantage regulations – which purport to provide antitrust immunity to certain approved health care collaboratives – are unnecessary because antitrust law already permits health care collaborations that benefit consumers. “We […]
Federal Appeals Court Upholds FTC Order that Found McWane, Inc. Unlawfully Maintained Monopoly in Domestic Pipe Fittings
The U.S. Court of Appeals for the Eleventh Circuit upheld a Federal Trade Commission Decision and Order finding that McWane, Inc., the largest U.S. supplier of ductile iron pipe fittings used in municipal and regional water distribution systems, unlawfully maintained its monopoly in the domestic fittings market through exclusionary conduct. “The Eleventh Circuit’s decision affirms […]
FTC Approves Final Order Preserving Competition in Market for BRAF- and MEK-Inhibitor Oncology Drugs
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Novartis AG’s $16 billion acquisition of GlaxoSmithKline’s portfolio of cancer-treatment drugs likely would be anticompetitive. Under the order, first announced in February 2015, Novartis has agreed to divest all assets related to its BRAF- and MEK-inhibitor drugs, currently […]
FTC Approves Final Order Preserving Competition for Generic Antibacterial Drug Minocycline
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Sun Pharmaceutical Industries Ltd.’s $4 billion acquisition of Ranbaxy Laboratories Ltd. would likely be anticompetitive. Under the order, first announced in January 2015, Sun is required to divest Ranbaxy’s interests in generic minocycline tablets to India-based Torrent Pharmaceuticals […]
FTC Approves Final Order Preserving Competition in Market for Treating Heartworm Disease in Dogs
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Eli Lilly and Company’s acquisition of Novartis Animal Health would likely be anticompetitive. Under the order, first announced in December 2014, Eli Lilly and Company has agreed to divest its Sentinel product line of medications for treating heartworm […]
FTC Approves Community Health Systems’ Application to Divest Riverview Regional Medical Center to Prime Healthcare
Following a public comment period, the Federal Trade Commission has approved an application from Community Health Systems to sell Riverview Regional Medical Center and its associated assets near Gadsden, Alabama. The divestiture was required under the FTC’s April 2014 final order settling charges that CHS’s acquisition of rival health system Health Management Associates, Inc. was […]
FTC Approves Surgery Center Holdings, Inc.’s Application to Divest Assets in Central Florida to Dr. Mark W. Hollmann
Following a public comment period, the Federal Trade Commission has approved an application from the owners of Surgery Center Holdings, known as Surgery Partners to divest Symbion Holdings Corporation’s ownership interest in the Blue Springs Surgery Center in Orange City, Florida, to Dr. Mark W. Hollmann. The divestiture is required by the Commission’s order, which […]
Statement by FTC Chairwoman Edith Ramirez on U.S. Supreme Court Ruling Regarding North Carolina Dental Board Matter
Federal Trade Commission Chairwoman Edith Ramirez issued the following statement regarding today’s decision by the U.S. Supreme Court in North Carolina State Board of Dental Examiners v. Federal Trade Commission: “Today, the Supreme Court affirmed the Federal Trade Commission’s position in recognizing that a state may not give private market participants unsupervised authority to […]